John C Thomas
CIK 1424620 · CFO and Secretary · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$664.9K
Companies
7
Total Filings
43
Lifetime Open-Market Net
-$1.91M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DWTX | Director | — | $1.55 | — | $0 | 3 | 2026-06-17 |
| Dogwood Therapeutics, Inc. (VIRI) Delisted | Director | 40 | $3.88 | $155 | $5.7K | 5 | 2024-02-28 |
| ImmunityBio, Inc. (NK) Delisted | Director | 221,363 | — | — | -$1.92M | 19 | 2020-12-11 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | — | — | — | $0 | 2 | 2018-08-13 |
| Innoveren Scientific, Inc. (MDVXW) Delisted | Director | 109,960 | — | — | $0 | 2 | 2017-11-01 |
| QLTI | Director | 24,500 | $27.14 | $664.9K | $0 | 7 | 2016-06-21 |
| Midatech Pharma US Inc. (DARA) Delisted | CFO and Secretary | 5,945 | — | — | $0 | 3 | 2012-05-17 |
Recent Filings · Page 2 of 5
43 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-08-13 | ImmunityBio, Inc. (NK) Delisted | Sell (S) | −60,000 | -$583.6K | EDGAR |
| 2020-06-11 | ImmunityBio, Inc. (NK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-12-16 | ImmunityBio, Inc. (NK) Delisted | Sell (S) | −30,000 | -$86.0K | EDGAR |
| 2019-12-12 | ImmunityBio, Inc. (NK) Delisted | Sell (S) | −10,000 | -$19.9K | EDGAR |
| 2019-09-09 | ImmunityBio, Inc. (NK) Delisted | Sell (S) | −24,000 | -$29.8K | EDGAR |
| 2019-06-07 | ImmunityBio, Inc. (NK) Delisted | Grant (A) | +92,592 | $0 | EDGAR |
| 2018-08-13 | NOVELION THERAPEUTICS INC. (NVLN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-11 | ImmunityBio, Inc. (NK) Delisted | Grant (A) | +27,322 | $0 | EDGAR |
| 2018-01-03 | ImmunityBio, Inc. (NK) Delisted | Gift (G) | −4,500 | $0 | EDGAR |
| 2017-12-20 | — | Buy (P) | +6,000 | $4.2K |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.